PALVELLA THERAPEUTICS, INC.
About PALVELLA THERAPEUTICS, INC.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $42.8M
- Net income
- -$41.7M
- Total assets
- $59.6M
- Market cap
- $1.6B
- Operating margin
- -1490.4%
- Net margin
- -1610.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.6M
- Operating expenses
- $38.6M
- Operating income
- -$38.6M
- Income tax
- $0
- Net income
- -$41.7M
- EPS (basic)
- $-3.71
- EPS (diluted)
- $-3.71
Balance sheet
- Total assets
- $59.6M
- Current assets
- $59.0M
- Total liabilities
- $31.6M
- Current liabilities
- $11.3M
- Shareholders’ equity
- $28.0M
Cash flow
- Operating cash flow
- -$25.0M
- Investing cash flow
- $25.6M
- Financing cash flow
- -$660.0K
- Net cash flow
- -$46.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-3.71
- Shares outstanding
- 15.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 16, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $41.7M in FY2023.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PALVELLA THERAPEUTICS, INC..
Write a review
News about PALVELLA THERAPEUTICS, INC.
News & sentiment via Polygon.io
